EPRX MEXC RealStocks
Own real EPRX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-15 23:36:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Eupraxia Pharmaceuticals Inc. (EPRX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $8.16, with a market capitalization of $548.24M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.63 to $9.32. This page covers its latest market performance, valuation, price trends and company information.
$548.24M | |
$7.81 | |
$8.23 | |
$7.67 | |
$7.81 | |
755.05K | |
699.74K | |
-- | |
$9.32 | |
$5.63 | |
-- | |
-- |
Eupraxia Pharmaceuticals Inc. (EPRX) last closed at $8.16 as of 2026-11-14 00:46:00, up 4.48% ($0.35) from the previous close of $7.81.
During the latest regular trading session, EPRX traded between $7.67 and $8.23, with a volume of 755.05K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Eupraxia Pharmaceuticals Inc. (EPRX) moved from $6.60 to $8.16, representing a gain of 23.58% ($1.56).
The stock traded between $6.30 and $8.49 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 601.54 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 68.5%
EPRX is currently trading at $8.16, placing it 68.5% of the way from its 52-week low of $5.63 to its 52-week high of $9.32. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
| Employees | 49 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Eupraxia Pharmaceuticals Inc. (EPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to EPRX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between EPRX shares and USD.
EPRX Shares to USD
1.00 EPRX shares = 8.156 USD
Calculations are estimates based on the latest available price and are for reference only.